Study Summary
This trial will test how well a cloud-based platform can recommend GDMT dosage for HFrEF patients.
Treatment Effectiveness
Effectiveness Progress
Study Objectives
3 Primary · 5 Secondary · Reporting Duration: 90 and 365 days
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
Control
1 of 2
Intervention
1 of 2
Active Control
Experimental Treatment
120 Total Participants · 2 Treatment Groups
Primary Treatment: BiovitalsHF · No Placebo Group · N/A
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 22 - 80 · All Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Who else is applying?
What state do they live in?
| Texas | 100.0% |
How old are they?
| 65+ | 100.0% |
What portion of applicants met pre-screening criteria?
| Did not meet criteria | 100.0% |
Frequently Asked Questions
Is enrollment open for this medical research project?
"According to the clinicaltrials.gov information, this medical trial presently requires more study participants. It was initially posted on January 27th 2020 and has been recently updated on July 21st 2022." - Anonymous Online Contributor
Are participants in this trial allowed to be over the age of twenty?
"Complying with the study's predetermined eligibility criteria, participants must be between 22 and 80 years old." - Anonymous Online Contributor
Are there any Canadian medical facilities currently testing this protocol?
"This research is being conducted at Premier Cardiovascular Institute in Dayton, Ohio; Cardiology and Medicine Clinic in Little Rock, Arkansas; ACRC Studies in San Diego, Texas; and 10 additional centres." - Anonymous Online Contributor
How many individuals are eligible for this investigation?
"To properly execute this trial, a total of 282 individuals meeting the study's criteria are necessary. Biofourmis Inc., the sponsor will be running it from various sites with Premier Cardiovascular Institute in Dayton and Cardiology and Medicine Clinic in Little Rock being two among them." - Anonymous Online Contributor
To whom is this clinical research open?
"This medical trial seeks 282 participants, aged between 22 and 80 that suffer from heart failure. In addition to these criteria, patients must have a left ventricular ejection fraction of 40% or less, be classified as NYHA Class II-III in the most recent screening assessment, and take doses of GDMT below 50%, with two medicines being taken at levels between 50-100%." - Anonymous Online Contributor